We are live on ! Find out more
CTIC

CTI BioPharma Corp. (DE) Common Stock

Delisted

CTIC was delisted on the 23rd of June, 2023.

85 hedge funds and large institutions have $100M invested in CTI BioPharma Corp. (DE) Common Stock in 2014 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 26 increasing their positions, 22 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,433% more call options, than puts

Call options by funds: $1.89M | Put options by funds: $123K

18% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 22

4% less funds holding

Funds holding: 8985 (-4)

13% less capital invested

Capital invested by funds: $116M → $100M (-$15.4M)

25% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 16

Holders
85
Holders Change
-4
Holders Change %
-4.49%
% of All Funds
2.47%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
12
Increased
26
Reduced
22
Closed
16
Calls
$1.89M
Puts
$123K
Net Calls
+$1.76M
Net Calls Change
-$84K
Name Holding Trade Value Shares
Change
Change in
Stake
EAM
1
Eagle Asset Management
Florida
$19M +$2.26M +86,785 +12%
State Street
2
State Street
Massachusetts
$13.3M -$2.42M -93,180 -14%
BIT
3
BlackRock Institutional Trust
California
$11.8M +$596K +22,924 +5%
Vanguard Group
4
Vanguard Group
Pennsylvania
$10.1M +$839K +32,280 +8%
Fidelity Investments
5
Fidelity Investments
Massachusetts
$8.21M
BFA
6
BlackRock Fund Advisors
California
$7.87M -$267K -10,288 -3%
Northern Trust
7
Northern Trust
Illinois
$3.69M +$95.2K +3,662 +2%
Jane Street
8
Jane Street
New York
$3.47M +$1.1M +42,374 +42%
Renaissance Technologies
9
Renaissance Technologies
New York
$2.45M +$827K +31,822 +46%
TA
10
Teachers Advisors
New York
$2.01M
Geode Capital Management
11
Geode Capital Management
Massachusetts
$1.93M +$133K +5,122 +7%
Bank of New York Mellon
12
Bank of New York Mellon
New York
$1.74M +$359K +13,810 +24%
Deutsche Bank
13
Deutsche Bank
Germany
$1.64M +$761K +29,285 +76%
TCIM
14
TIAA CREF Investment Management
New York
$1.19M -$149K -5,714 -10%
Goldman Sachs
15
Goldman Sachs
New York
$1.09M +$131K +5,042 +13%
WT
16
Washington Trust
Rhode Island
$994K
BIM
17
BlackRock Investment Management
Delaware
$948K +$7.57K +291 +0.7%
California Public Employees Retirement System
18
California Public Employees Retirement System
California
$883K
TCT
19
TIAA CREF Trust
Missouri
$717K
California State Teachers Retirement System (CalSTRS)
20
California State Teachers Retirement System (CalSTRS)
California
$599K +$7.31K +281 +1%
Charles Schwab
21
Charles Schwab
California
$462K
Swiss National Bank
22
Swiss National Bank
Switzerland
$461K +$131K +5,020 +36%
Barclays
23
Barclays
United Kingdom
$449K +$410K +15,752 +234%
AllianceBernstein
24
AllianceBernstein
Tennessee
$398K -$82.7K -3,180 -16%
UCFA
25
United Capital Financial Advisors
Texas
$364K -$46.7K -1,797 -11%

CTIC Hedge Fund Activity: Q3 2014 in Review

85 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in CTI BioPharma Corp. (DE) Common Stock (CTIC) for Q3 2014, worth a combined $100M — down 13% from $116M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of CTIC and 12 opened new positions — a net loss of 4 holders — while 22 trimmed existing stakes and 26 added.

The largest buyer was Eagle Asset Management, adding an estimated $2.26M. The largest seller was State Street, cutting an estimated $2.42M.

  • 85 institutional investors held CTI BioPharma Corp. (DE) Common Stock (CTIC) as of Q3 2014, down from 89 in Q2 2014.
  • Funds reported $100M of CTI BioPharma Corp. (DE) Common Stock stock for Q3 2014, down 13% quarter-over-quarter.
  • 12 funds opened new CTI BioPharma Corp. (DE) Common Stock positions in Q3 2014 and 16 closed out, a net change of -4 holders.
  • The largest CTI BioPharma Corp. (DE) Common Stock buyer in Q3 2014 was Eagle Asset Management, an estimated $2.26M added.
  • The largest CTI BioPharma Corp. (DE) Common Stock seller in Q3 2014 was State Street, an estimated $2.42M sold.

Based on aggregated 13F filings for Q3 2014.